Dapiprazole: Difference between revisions
No edit summary |
No edit summary |
||
| Line 50: | Line 50: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Dapiprazole''' ('''Rev-Eyes''') is an [[alpha blocker]]. It is used to reverse [[mydriasis]] after [[eye examination]].<ref>{{cite journal |title = A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation |author = Doughty, Michael J.; Lyle, William M. |journal = Optometry & Vision Science |date = May 1992 |volume = 69 |issue = 5 |url = http://journals.lww.com/optvissci/Abstract/1992/05000/A_Review_of_the_Clinical_Pharmacokinetics_of.5.aspx}}</ref> | '''Dapiprazole''' ('''Rev-Eyes''') is an [[alpha blocker]]. It is used to reverse [[mydriasis]] after [[eye examination]].<ref>{{cite journal |title = A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation |author = Doughty, Michael J.; Lyle, William M. |journal = Optometry & Vision Science |date = May 1992 |volume = 69 |issue = 5 |url = http://journals.lww.com/optvissci/Abstract/1992/05000/A_Review_of_the_Clinical_Pharmacokinetics_of.5.aspx}}</ref> | ||
| Line 62: | Line 59: | ||
{{Antiglaucoma preparations and miotics}} | {{Antiglaucoma preparations and miotics}} | ||
[[Category:Alpha blockers]] | [[Category:Alpha blockers]] | ||
[[Category:Piperazines]] | [[Category:Piperazines]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Latest revision as of 14:53, 10 April 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a601043 |
| Pregnancy category |
|
| Routes of administration | Topical (eye drops) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible when administered topically |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H27N5 |
| Molar mass | 325.451 g/mol |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
|
WikiDoc Resources for Dapiprazole |
|
Articles |
|---|
|
Most recent articles on Dapiprazole Most cited articles on Dapiprazole |
|
Media |
|
Powerpoint slides on Dapiprazole |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dapiprazole at Clinical Trials.gov Clinical Trials on Dapiprazole at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dapiprazole
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dapiprazole Discussion groups on Dapiprazole Patient Handouts on Dapiprazole Directions to Hospitals Treating Dapiprazole Risk calculators and risk factors for Dapiprazole
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dapiprazole |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dapiprazole (Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination.[1]
References
- ↑ Doughty, Michael J.; Lyle, William M. (May 1992). "A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation". Optometry & Vision Science. 69 (5).
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugboxes which contain changes to verified fields
- Alpha blockers
- Piperazines
- Drug